FREMONT, Calif. — WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis company, today announced that Scott R. Davidson and Joseph F. Pesce, CPA, have joined the company’s Board of Directors.

Scott R. Davidson currently serves as Managing Director at Great Point Partners, Greenwich, CT. As part of his investment functions, he leads Great Point Partners’ medical devices and diagnostics investing efforts. Prior to joining Great Point, he served in various capacities at Piper Jaffray & Co.; Bear, Stearns & Co.; Robertson Stephens & Co.; and Canaan Partners. He holds an A.B. from Harvard College and an M.B.A. from Stanford Graduate School of Business where he was an Arjay Miller Scholar.

Joseph F. Pesce has been a Managing Director and Operating Partner of Great Point Partners, LLC since January 1, 2011. Previously, he was the Chief Financial Officer and Treasurer of Thomas H. Lee Partners, whom he joined in 2001, and where he was promoted to Managing Director and Chief of Operations in 2006. Most recently, he has served as that firm’s Chief Risk Officer. Prior to that, Mr. Pesce spent over 25 years in senior financial positions in high technology, healthcare and consulting services companies. Mr. Pesce received an A.B. in Mathematics with honors from Boston College and an M.B.A. from the Wharton School of the University of Pennsylvania. He is a Certified Public Accountant and a member of The American Institute of Certified Public Accountants, the Massachusetts Society of Certified Public Accountants and Financial Executives International.

About WaferGen and the SmartChip Real-Time PCR System

WaferGen Biosystems, Inc., an emerging genomic analysis company in the early stage of commercialization, offers the transformative SmartChip Real-Time PCR System—a next-generation Real-Time PCR system for profiling and validation of gene expression patterns (biomarkers) on a single platform. The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and Single Nucleotide Polymorphism (SNP) genotyping. WaferGen also offers Quick-Turnaround SmartChip Custom (User-Defined) Panels to enable validation studies of specific genes of interest through customization of high-throughput, real-time PCR SmartChip assay panels—all on a quick-turnaround basis.

In addition, the Company offers an innovative fee-based service for gene-expression profiling using the SmartChip System. For additional information, please see http://www.wafergen.com